Brokers Set Expectations for Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vaxcyte in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of ($7.02) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

A number of other analysts also recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte has an average rating of “Buy” and an average target price of $145.71.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $89.97 on Thursday. Vaxcyte has a 52-week low of $58.10 and a 52-week high of $121.06. The business’s 50 day simple moving average is $87.29 and its 200 day simple moving average is $93.88. The firm has a market cap of $11.21 billion, a PE ratio of -19.56 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the business earned ($0.91) earnings per share.

Insiders Place Their Bets

In related news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $106.80, for a total transaction of $854,400.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $21,968,226. The trade was a 3.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,982 shares of company stock valued at $8,108,425. 3.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vaxcyte

Several institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV lifted its stake in shares of Vaxcyte by 78.0% during the 4th quarter. KBC Group NV now owns 4,775 shares of the company’s stock worth $391,000 after buying an additional 2,092 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Vaxcyte by 125.1% during the fourth quarter. Blue Trust Inc. now owns 835 shares of the company’s stock worth $68,000 after acquiring an additional 464 shares during the period. Avior Wealth Management LLC grew its position in shares of Vaxcyte by 21.1% in the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company’s stock valued at $528,000 after purchasing an additional 1,124 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Vaxcyte by 21.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company’s stock worth $220,000 after purchasing an additional 475 shares during the period. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Vaxcyte by 15.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 74,907 shares of the company’s stock worth $6,132,000 after purchasing an additional 10,243 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.